35 Non-Small Cell Lung Cancer Clinical Trials in New York, NY (2026)

Q: How do I join a clinical trial in New York?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you.

Recruiting Non-Small Cell Lung Cancer Studies in New York

NCT07111520Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treat...

New York, NYPHASE1880 participantsBioNTech SE

View Study Details

NCT05379985Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

New York, NYPHASE1754 participantsRevolution Medicines, Inc.

View Study Details

NCT06917079Recruiting

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumo...

New York, NYPHASE1665 participantsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

View Study Details

NCT06040541Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors....

New York, NYPHASE1604 participantsRevolution Medicines, Inc.

View Study Details

NCT07349537Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or...

New York, NYPHASE1574 participantsRevolution Medicines, Inc.

View Study Details

NCT07660094Recruiting

Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)

This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non...

New York, NYPHASE3500 participantsCandel Therapeutics, Inc.

View Study Details

NCT04686305Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-s...

New York, NYPHASE1304 participantsAstraZeneca

View Study Details

NCT05424029Recruiting

Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors con...

New York, NY200 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06855771Recruiting

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion ...

New York, NYPHASE2182 participantsBristol-Myers Squibb

View Study Details

NCT07491497Recruiting

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evalu...

New York, NYPHASE1160 participantsTRIANA Biomedicines, Inc.

View Study Details

NCT07680764Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-lin...

New York, NYPHASE2160 participantsBristol-Myers Squibb

View Study Details

NCT06626243Recruiting

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced ...

New York, NY140 participantsScientific Institute San Raffaele

View Study Details

NCT07246863Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivoluma...

New York, NYPHASE2131 participantsCatalYm GmbH

View Study Details

NCT06667908Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can i...

New York, NYPHASE2130 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT06218914Recruiting

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors....

New York, NYPHASE1108 participantsAstraZeneca

View Study Details

NCT07098988Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemot...

New York, NYPHASE2107 participantsCatalYm GmbH

View Study Details

NCT07659782Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer...

New York, NYPHASE2105 participantsVerastem, Inc.

View Study Details

NCT07690917Recruiting

A Study of a New PET Scanner in People With Cancer

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better P...

New York, NY90 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT01639508Recruiting

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or incre...

New York, NYPHASE286 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06046495Recruiting

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSC...

New York, NYPHASE181 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT05657873Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-sm...

New York, NYPHASE268 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07535437Recruiting

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

The researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small ce...

New York, NYPHASE166 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06010329Recruiting

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutat...

New York, NYPHASE266 participantsTeligene US

View Study Details

NCT06841055Recruiting

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy

This is a Phase II, multisite, open-label, single arm study with two parts in participants with advanced/metastatic NSCLC which progressed after a first-line chemoimmunotherapy. Part 1 is safety run-...

New York, NYPHASE260 participantsBioNTech SE

View Study Details

NCT07218601Recruiting

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after ...

New York, NYPHASE260 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07874490Recruiting

Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

This single-site, biomarker-enriched, randomized Phase II study will evaluate osimertinib with or without cyclosporine A (CsA) in metastatic epidermal growth factor receptor (EGFR )-mutant non-small c...

New York, NYPHASE260 participantsNYU Langone Health

View Study Details

NCT07535463Recruiting

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

The researchers are doing this study to test the safety of ivonescimab given in combination with standard chemotherapy and stereotactic radiosurgery (SRS) in people with non-small cell lung cancer (NS...

New York, NYPHASE153 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT05589818Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease sta...

New York, NYPHASE245 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT05815173Recruiting

Ladarixin With Sotorasib in Advanced NSCLC

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC)....

New York, NYPHASE140 participantsNYU Langone Health

View Study Details

NCT06582771Recruiting

A Study of Sotorasib in People with Non-Small Cell Lung Cancer

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received t...

New York, NYPHASE239 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07594522Recruiting

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer ...

New York, NYPHASE136 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07323732Recruiting

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and...

New York, NYPHASE225 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06088771Recruiting

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will incl...

New York, NYPHASE121 participantsIcahn School of Medicine at Mount Sinai

View Study Details

NCT07619339Recruiting

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is posit...

New York, NYPHASE116 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07428044Recruiting

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab d...

New York, NYPHASE214 participantsMemorial Sloan Kettering Cancer Center

View Study Details

About Non-Small Cell Lung Cancer Clinical Trials in New York

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Treatment has been transformed by targeted therapies and immunotherapy based on specific genetic markers.

There are currently 35 non-small cell lung cancer clinical trials recruiting participants in New York, NY. These studies are seeking a combined 6,630 participants. Research is being sponsored by BioNTech SE, Revolution Medicines, Inc., TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Small Cell Lung Cancer Clinical Trials in New York — FAQ

Are there non-small cell lung cancer clinical trials in New York?

Yes, there are 35 non-small cell lung cancer clinical trials currently recruiting in New York, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What non-small cell lung cancer treatments are being tested?

The 35 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for non-small cell lung cancer.

Data updated October 17, 2026 from ClinicalTrials.gov